- Details
- Siamak Daneshmand shares insights Phase 2 Study of the "Efficacy and Safety of Erdafitinib in Patients with Bacillus Calmette-Guérin-Unresponsive, High-Risk Non–muscle-Invasive Bladder Cancer with FGFR3/2 Alterations in THOR-2". For patients that present with NMIBC who have carcinoma in situ (CIS), there is a high risk of disease progression. In more advanced bladder cancer FGFR inhibition has dem...
|
- Details
- Lorelei Mucci and Daniel George join Alicia Morgans to discuss the IRONMAN registry, the International Registry for Men with Advanced Prostate Cancer. The registry has actively enrolled 3,200 patients with hormone-sensitive or castration-resistant prostate cancer from 14 countries worldwide. The registry includes a diverse population in terms of geography, socioeconomic status, the type of center...
|
- Details
- Matt Galsky joins Sam Chang in a conversation about the long-term results of the IMvigor130 randomized phase III study which evaluated the use of atezolizumab in combination with platinum/gemcitabine chemotherapy versus platinum/gemcitabine chemotherapy alone in patients with metastatic urothelial carcinoma. The study used a hierarchical statistical analysis plan, and the first analysis showed a s...
|
- Details
- Jason Brown joins Sam Chang in conversation on the results of neoadjuvant combination therapy prior to cystectomy and nephroureterectomy. This is a multi-institutional phase Ib/II two-stage study investigating chemo-immunotherapy in patients with cisplatin-eligible or ineligible muscle-invasive urothelial carcinoma. The treatment for cisplatin-eligible patients included gemcitabine, cisplatin, and...
|
- Details
- Fabien Moinard-Butot from the Medical Oncology Department at the Strasbourg Cancer Institute discusses a retrospective single-center study that explored local therapy for residual disease in a cohort of patients with advanced renal cell carcinoma. The primary endpoint was the complete response rate. In the study, 80 patients were treated with immunotherapy-based combinations with metastatic renal...
|
- Details
- In this discussion between Alicia Morgans and Kim Chi, they discuss the challenges, controversies, and opportunities of PARP inhibitor combinations with androgen receptor signaling inhibitors. Dr. Kim Chi summarized the MAGNITUDE trial that studied metastatic CRPC patients who received ARPI or abiraterone vs. abiraterone plus niraparib. The trial's pre-screening process selected patients with homo...
|
- Details
- Alan Bryce joins Alicia Morgans in a discussion on the interim overall survival data from TRITON3, a Phase 3 study comparing rucaparib to physician's choice of therapy in metastatic castration-resistant prostate cancer associated with homologous recombination deficiency. Eligible patients had received at least one prior androgen receptor pathway inhibitor, were chemotherapy-naïve in the CRPC setti...
|
- Details
- Matthew Galsky and Alicia Morgans discuss the co-primary endpoint analysis of HCRN GU 16-257, a phase II clinical trial investigating the efficacy of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer who are undergoing selective bladder-sparing treatment. The trial investigated whether a subset of patients could be treated with systemic therapy and avoid definit...
|
- Details
- Tanya Jindal and Vadim Koshkin join Petros Grivas to discuss their work to help identify potential biomarkers of response to enfortumab vedotin (EV) in patients with advanced urothelial carcinoma using a patient cohort in the UNITE dataset. The UNITE study researchers analyzed biomarkers associated with enfortumab vedotin (EV) treatment outcomes in patients with advanced urothelial carcinoma. They...
|
- Details
- Matthew Milowsky joins Sam Chang in a discussion on the patient-reported outcomes from Cohort K of the EV-103 Phase 1b/2 study which analyzed the impact of enfortumab vedotin (EV) alone or combined with pembrolizumab on patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin. The objective was to describe the impact on the patients' quality of life (QoL)...
|
